US Patent Issued to HuidaGene Therapeutics (Singapore) on Oct. 28 for "Type VI-E and type VI-F CRISPR-Cas system and uses thereof" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,454,690, issued on Oct. 28, was assigned to HuidaGene Therapeutics (Singapore) Pte. Ltd. (Singapore).

"Type VI-E and type VI-F CRISPR-Cas system and uses thereof" was invented by Hui Yang (Shanghai), Chunlong Xu (Shanghai), Yingsi Zhou (Shanghai) and Qingquan Xiao (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides novel CRISPR/Cas compositions and uses thereof for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13e or Cas13f effector protein, and at least one targeting nucleic acid component such as a guide RNA (gRN...